U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Assessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Assessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications Draft Guidance for Industry July 2021

Download the Draft Guidance Document Read the Federal Register Notice
Draft

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2020-D-2323
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This guidance provides recommendations for clinical trials designed to assess the adhesion performance of transdermal and topical delivery systems (collectively referred to as TDS). Adhesion performance is defined in this guidance as whether the TDS fully adheres to the subject in the applied location for the duration of use of the TDS. Adhesion performance can affect both safety and effectiveness of TDS products because adhesion failures can result in reduced effectiveness caused by suboptimal dosing or potentially increased exposure when a new TDS needs to be applied sooner than the scheduled dose. Additionally, partial or full detachment of a TDS from a patient’s skin may result in unintentional exposure of the active pharmaceutical ingredient to a partner, child, or other individual, potentially exposing them to the drug’s toxicity. Adhesion performance may also inform the Dosage and Administration section of labeling.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2020-D-2323.

Back to Top